JPWO2020163268A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020163268A5 JPWO2020163268A5 JP2021546360A JP2021546360A JPWO2020163268A5 JP WO2020163268 A5 JPWO2020163268 A5 JP WO2020163268A5 JP 2021546360 A JP2021546360 A JP 2021546360A JP 2021546360 A JP2021546360 A JP 2021546360A JP WO2020163268 A5 JPWO2020163268 A5 JP WO2020163268A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- formula
- motor neuron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 206010001497 Agitation Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 210000002161 motor neuron Anatomy 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024033668A JP2024063191A (ja) | 2019-02-06 | 2024-03-06 | Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962801716P | 2019-02-06 | 2019-02-06 | |
| US62/801,716 | 2019-02-06 | ||
| US201962811038P | 2019-02-27 | 2019-02-27 | |
| US62/811,038 | 2019-02-27 | ||
| PCT/US2020/016499 WO2020163268A1 (en) | 2019-02-06 | 2020-02-04 | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024033668A Division JP2024063191A (ja) | 2019-02-06 | 2024-03-06 | Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022519744A JP2022519744A (ja) | 2022-03-24 |
| JPWO2020163268A5 true JPWO2020163268A5 (zh) | 2023-02-13 |
| JP7451543B2 JP7451543B2 (ja) | 2024-03-18 |
Family
ID=69743945
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021546360A Active JP7451543B2 (ja) | 2019-02-06 | 2020-02-04 | Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体 |
| JP2024033668A Pending JP2024063191A (ja) | 2019-02-06 | 2024-03-06 | Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024033668A Pending JP2024063191A (ja) | 2019-02-06 | 2024-03-06 | Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11208383B2 (zh) |
| EP (1) | EP3921030B1 (zh) |
| JP (2) | JP7451543B2 (zh) |
| KR (1) | KR20210126040A (zh) |
| CN (1) | CN113692304A (zh) |
| AU (1) | AU2020218180A1 (zh) |
| BR (1) | BR112021015544A2 (zh) |
| CA (1) | CA3128975A1 (zh) |
| DK (1) | DK3921030T3 (zh) |
| ES (1) | ES2968807T3 (zh) |
| FI (1) | FI3921030T3 (zh) |
| HR (1) | HRP20240012T1 (zh) |
| HU (1) | HUE064734T2 (zh) |
| IL (1) | IL285113A (zh) |
| LT (1) | LT3921030T (zh) |
| MX (1) | MX2021009396A (zh) |
| PL (1) | PL3921030T3 (zh) |
| PT (1) | PT3921030T (zh) |
| RS (1) | RS65040B1 (zh) |
| SG (1) | SG11202108599SA (zh) |
| SI (1) | SI3921030T1 (zh) |
| WO (1) | WO2020163268A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020163268A1 (en) * | 2019-02-06 | 2020-08-13 | Eli Lilly And Company | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
| TW202216660A (zh) | 2020-06-25 | 2022-05-01 | 瑞士商愛杜西亞製藥有限公司 | 環丁基-脲衍生物 |
| TW202330471A (zh) * | 2021-09-30 | 2023-08-01 | 日商住友製藥股份有限公司 | 環丙醯胺衍生物 |
| WO2023091554A1 (en) | 2021-11-19 | 2023-05-25 | Icagen, Llc | Novel heteroaryl-urea compounds as kv7.2 inhibitors |
| WO2023091461A1 (en) | 2021-11-19 | 2023-05-25 | Icagen, Llc | Pyridine compounds as kv7.2 enhancers |
| WO2023121992A1 (en) | 2021-12-22 | 2023-06-29 | Icagen, Llc | Cyclopropyl compounds |
| WO2023158584A1 (en) | 2022-02-15 | 2023-08-24 | Icagen, Llc | New bicyclopentane derivatives |
| WO2024121048A1 (en) * | 2022-12-05 | 2024-06-13 | Angelini Pharma S.P.A. | Urea compounds as activators of potassium channels kv7.2/7.3 useful in the treatment of cns and pns disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6300352B1 (en) * | 1997-03-25 | 2001-10-09 | Astrazeneca Ab | Pyridine derivatives and pharmaceutical compositions containing them |
| CN100345823C (zh) * | 2003-01-14 | 2007-10-31 | 赛特凯恩蒂克公司 | 化合物、组合物及方法 |
| MXPA06011807A (es) | 2004-04-13 | 2007-02-21 | Icagen Inc | Piridinas policiclicas como moduladores del canal del ion de potasio. |
| CN1993347A (zh) * | 2004-07-29 | 2007-07-04 | 默克公司 | 钾通道抑制剂 |
| WO2010036316A1 (en) | 2008-09-24 | 2010-04-01 | Yangbo Feng | Urea and carbamate compounds and analogs as kinase inhibitors |
| BRPI1010884A2 (pt) * | 2009-06-08 | 2016-03-15 | Gilead Sciences Inc | composto inibidores hdac de alcanoilamino benzamida anilina |
| WO2012116440A1 (en) * | 2011-03-03 | 2012-09-07 | Zalicus Pharmaceuticals Ltd. | Benzimidazole inhibitors of the sodium channel |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| CN103709097A (zh) | 2012-09-28 | 2014-04-09 | 中国科学院上海药物研究所 | 1,3-取代脲或硫脲化合物、其制备方法、药物组合物和应用 |
| CN112047927A (zh) | 2013-03-15 | 2020-12-08 | 德西费拉制药有限责任公司 | 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物 |
| JP6577479B2 (ja) | 2014-02-27 | 2019-09-18 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｎａｖ チャンネル阻害剤としてのヘテロ環化合物及びその使用 |
| MX2017005044A (es) | 2014-10-24 | 2017-07-04 | Ono Pharmaceutical Co | Activador de canales de kcnq2-5. |
| ES2866324T3 (es) | 2016-04-22 | 2021-10-19 | Ono Pharmaceutical Co | Derivados de 1-(1-hidroxi-2,3-dihidro-1H-inden5-il)-urea y compuestos similares como activadores del canal KCNQ2-5 para el tratamiento de la disuria |
| WO2020163268A1 (en) * | 2019-02-06 | 2020-08-13 | Eli Lilly And Company | 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators |
-
2020
- 2020-02-04 WO PCT/US2020/016499 patent/WO2020163268A1/en active Application Filing
- 2020-02-04 HR HRP20240012TT patent/HRP20240012T1/hr unknown
- 2020-02-04 FI FIEP20709409.5T patent/FI3921030T3/fi active
- 2020-02-04 RS RS20240009A patent/RS65040B1/sr unknown
- 2020-02-04 PL PL20709409.5T patent/PL3921030T3/pl unknown
- 2020-02-04 KR KR1020217028040A patent/KR20210126040A/ko unknown
- 2020-02-04 SG SG11202108599SA patent/SG11202108599SA/en unknown
- 2020-02-04 CA CA3128975A patent/CA3128975A1/en active Pending
- 2020-02-04 US US16/781,148 patent/US11208383B2/en active Active
- 2020-02-04 SI SI202030316T patent/SI3921030T1/sl unknown
- 2020-02-04 EP EP20709409.5A patent/EP3921030B1/en active Active
- 2020-02-04 CN CN202080012797.0A patent/CN113692304A/zh active Pending
- 2020-02-04 LT LTEPPCT/US2020/016499T patent/LT3921030T/lt unknown
- 2020-02-04 BR BR112021015544-9A patent/BR112021015544A2/pt unknown
- 2020-02-04 MX MX2021009396A patent/MX2021009396A/es unknown
- 2020-02-04 PT PT207094095T patent/PT3921030T/pt unknown
- 2020-02-04 DK DK20709409.5T patent/DK3921030T3/da active
- 2020-02-04 ES ES20709409T patent/ES2968807T3/es active Active
- 2020-02-04 AU AU2020218180A patent/AU2020218180A1/en active Pending
- 2020-02-04 JP JP2021546360A patent/JP7451543B2/ja active Active
- 2020-02-04 HU HUE20709409A patent/HUE064734T2/hu unknown
-
2021
- 2021-07-25 IL IL285113A patent/IL285113A/en unknown
- 2021-11-19 US US17/531,000 patent/US11840516B2/en active Active
-
2023
- 2023-11-09 US US18/388,299 patent/US20240076269A1/en active Pending
-
2024
- 2024-03-06 JP JP2024033668A patent/JP2024063191A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022121594A5 (zh) | ||
| JP2023002662A5 (zh) | ||
| JP2020189864A5 (zh) | ||
| JP2022191257A5 (zh) | ||
| RU2007101653A (ru) | Производные 1-азабицикло[3.3.1]нонанов | |
| CA2472581A1 (en) | Tricyclic-bis-enone derivatives and methods of use thereof | |
| JP2020507589A5 (zh) | ||
| JP2009511568A5 (zh) | ||
| JP2002523500A5 (zh) | ||
| JP2017511339A5 (zh) | ||
| JP7373508B2 (ja) | エキノカンジン抗真菌剤の合成 | |
| JP2007530703A5 (zh) | ||
| JPWO2020163268A5 (zh) | ||
| WO2021191812A1 (en) | Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| JP2019533660A5 (zh) | ||
| JP2018140987A5 (zh) | ||
| JPWO2020092019A5 (zh) | ||
| JP5792322B2 (ja) | ビタミンｄおよびメトホルミン含有医薬組成物 | |
| JP7149991B2 (ja) | 発泡剤を含む抗微生物組成物 | |
| JP2006517561A5 (zh) | ||
| JPWO2019232130A5 (zh) | ||
| JPWO2020037152A5 (zh) | ||
| JPWO2020033359A5 (zh) | ||
| WO2024010030A1 (ja) | 血中マイオスタチン低下剤 | |
| JPWO2020023324A5 (zh) |